A DNA helix running into a clock face whose hands turn backwards
Illustration: Cracked Open
Longevity Frontiers Emerging

Rewinding the cell clock

From mice that lived 30 percent longer to the first human dosed in 2026: where partial reprogramming really stands.

By the Cracked Open editors · Issue No. 1 · November 2026

Emerging

The animal results are peer reviewed and striking. The human evidence is a single small safety trial with early, uncontrolled signals. Promising, not proven.

In 2006 the Japanese scientist Shinya Yamanaka showed that four genes could turn an adult cell back into an embryonic like stem cell. It won him a Nobel Prize. It also raised a tantalising question: if a cell can be wound all the way back to the beginning, could it be wound back just a little, making it younger without making it something else?

The mouse that lived longer

The first serious answer came in December 2016 from Juan Carlos Izpisua Belmonte's lab at the Salk Institute, published in the journal Cell. Switching the four Yamanaka factors on continuously in living mice had been disastrous, causing tumours or death. So the team switched them on briefly and in cycles. In mice with a premature ageing disease, the treatment reversed several markers of ageing and extended lifespan by about 30 percent.

The mouse that saw again

In 2020 David Sinclair's group at Harvard went further, in Nature. They dropped the riskiest of the four genes, the cancer linked c Myc, and used the other three, known as OSK. Delivered into the eye, the treatment regenerated damaged optic nerves and reversed vision loss in a mouse model of glaucoma and in old mice. The effect depended on enzymes that remove chemical marks from DNA, supporting the idea that cells keep a recoverable memory of being young.

The question is no longer whether cells can be rejuvenated in a dish. It is whether it can be done safely in a person.

The money

Investors noticed. In January 2022 Altos Labs launched with three billion dollars of committed funding to pursue what it calls cellular rejuvenation programming, recruiting Belmonte among many leading scientists. Several other companies are racing on the same idea.

The first human

In January 2026 the US Food and Drug Administration cleared Life Biosciences, a company Sinclair founded, to test its OSK therapy ER 100 in people with two eye conditions: open angle glaucoma and non arteritic anterior ischemic optic neuropathy, a cause of sudden vision loss with no approved treatment. On 9 June 2026 the first participant was dosed. It was the first time a partial epigenetic reprogramming therapy had been given to a human.

Interim results reported in October 2026 covered three participants. The single eye injection was well tolerated through 56 days, with no serious adverse events. Two of the three glaucoma patients showed improvement in parts of their visual field.

The gap

Read that last result carefully. Three people. No control group. Everyone knew they were treated. Fifty six days of follow up. It is a safety study, and a successful one so far, but it says nothing yet about whether the benefit is real, lasting or applicable beyond the eye. The eye was chosen precisely because it is a small, contained organ where a gene therapy can be delivered locally.

Partial reprogramming has moved from science fiction to the clinic in ten years. That is remarkable. The distance from a treated optic nerve to a younger human body is still enormous, and anyone selling rejuvenation today is selling ahead of the evidence.

How we label our articles. Every story carries one of four evidence labels. See what they mean, or explore the key ideas in Concepts.

Sources

  1. Ocampo A. et al., In vivo amelioration of age associated hallmarks by partial reprogramming, Cell, 2016
  2. Lu Y. et al., Reprogramming to recover youthful epigenetic information and restore vision, Nature, 2020
  3. Life Biosciences, FDA clearance of IND application for ER 100, January 2026
  4. ClinicalTrials.gov, NCT07290244: Evaluating ER 100 for safety in glaucoma and NAION
  5. López Otín C. et al., Hallmarks of aging: an expanding universe, Cell, 2023

Get the next issue

One email when a new issue opens.